Oncomine Focus Assay

• Hot spot screening of relevant, druggable mutations, copy number changes and fusions for various Cancers
• Analysing of 1000 variants across 52 genes for -- cancers
• ACMG/AMP guidelines-based reporting with drugs and target information
• NGS based assay eliminate need of multiple technology FISH, IHC, Realtime
• High Sensitivity and Specificity
• Identifies druggable targets in various cancers and unknown primary

All types of solid tumors showing the presence of mutation and copy number variation, in the genes present in oncomine focus assay. Hence, this assay best suited to identify druggable mutation, driver mutation or CNV changes and prognostic bio-markers.

Analyzed using: cbioportal.org.

Multiple tumors such as Bone sarcoma, breast cancer, CRC, cholangiocarcinoma, gastric cancer, Head and neck cancer, melanoma, lung cancer, prostate cancer, salivary gland carcinoma, thyroid cancer, uterine sarcoma are showing fusion drivers in >2% of the cases, that can be detected by Oncomine focus assay.

Analyzed using: cbioportal.org.

• Can identify mutation with 5% variant allele frequency (5% mutant DNA, among 95% normal DNA).
• LOD for RNA fusion is 255 copies of RNA.
• RNA fusions and CNV changes detected by NGS has equal sensitivity to FISH.
• Hence multiple testing is not required.